{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:04:17Z","timestamp":1790643857313,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06560-2","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T02:19:20Z","timestamp":1764901160000},"page":"6229-6235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Siltuximab monotherapy improves progression free survival compared to rituximab-based therapies in patients with idiopathic multicentric Castleman disease; indirect comparison of studies using single-arm metanalysis method and the generalized linear mixed model"],"prefix":"10.1007","volume":"104","author":[{"given":"Lazaros","family":"Karatisidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Mprotsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios","family":"Intzes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Zagoridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Vrachiolias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Karatisidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoi","family":"Bezirgianidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Liapis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kotsianidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Spanoudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"6560_CR1","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1182\/blood-2018-05-848671","volume":"132","author":"DC Fajgenbaum","year":"2018","unstructured":"Fajgenbaum DC (2018) Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood 132:2323\u20132330","journal-title":"Blood"},{"key":"6560_CR2","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","volume":"132","author":"F van Rhee","year":"2018","unstructured":"van Rhee F, Voorhees P, Dispenzieri A et al (2018) International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132:2115\u20132124","journal-title":"Blood"},{"key":"6560_CR3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1177\/0956462414562050","volume":"26","author":"H Sasaki","year":"2015","unstructured":"Sasaki H, Maeda T, Hara Y et al (2015) Human herpes virus-8-associated multicentric castleman\u2019s disease in an HIV-positive patient presenting with relapsing and remitting hyponatraemia. Int J STD AIDS 26:909\u2013911","journal-title":"Int J STD AIDS"},{"key":"6560_CR4","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1182\/blood-2016-10-747477","volume":"129","author":"AD Pria","year":"2017","unstructured":"Pria AD, Pinato D, Roe J et al (2017) Relapse of HHV8-positive multicentric castleman disease following rituximab-based therapy in HIV-positive patients. Blood 129:2143\u20132147","journal-title":"Blood"},{"key":"6560_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.hoc.2017.09.003","volume":"32","author":"K Yoshizaki","year":"2018","unstructured":"Yoshizaki K, Murayama S, Ito H, Koga T (2018) The role of interleukin-6 in Castleman disease. Hematol Oncol Clin North Am 32:23\u201336","journal-title":"Hematol Oncol Clin North Am"},{"key":"6560_CR6","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T et al (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112:3959\u20133964","journal-title":"Blood"},{"key":"6560_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/bjh.15019","volume":"180","author":"E Oksenhendler","year":"2018","unstructured":"Oksenhendler E, Boutboul D, Fajgenbaum D et al (2018) The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol 180:206\u2013216","journal-title":"Br J Haematol"},{"key":"6560_CR8","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood.2019000931","volume":"135","author":"A Dispenzieri","year":"2020","unstructured":"Dispenzieri A, Fajgenbaum DC (2020) Overview of castleman disease. Blood 135:1353\u20131364","journal-title":"Blood"},{"key":"6560_CR9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s40265-014-0249-x","volume":"74","author":"A Markham","year":"2014","unstructured":"Markham A, Patel T (2014) Siltuximab: first global approval. Drugs 74:1147\u20131152","journal-title":"Drugs"},{"key":"6560_CR10","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","volume":"106","author":"N Nishimoto","year":"2005","unstructured":"Nishimoto N, Kanakura Y, Aozasa K et al (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627\u20132632","journal-title":"Blood"},{"key":"6560_CR11","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/S2352-3026(19)30257-1","volume":"7","author":"F van Rhee","year":"2020","unstructured":"van Rhee F, Casper C, Voorhees PM et al (2020) Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematol 7:e209\u2013e217","journal-title":"Lancet Haematol"},{"key":"6560_CR12","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.1182\/bloodadvances.2022007112","volume":"6","author":"F van Rhee","year":"2022","unstructured":"van Rhee F, Rosenthal A, Kanhai K et al (2022) Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv 6:4773\u20134781","journal-title":"Blood Adv"},{"key":"6560_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.14740\/jh1343","volume":"13","author":"C Jitaru","year":"2024","unstructured":"Jitaru C, Symeonidis A, Badelita S et al (2024) Siltuximab in idiopathic multicentric Castleman disease: real-world experience. J Hematol 13:207\u2013215","journal-title":"J Hematol"},{"key":"6560_CR14","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood-2016-11-748855","volume":"129","author":"L Yu","year":"2017","unstructured":"Yu L, Tu M, Cortes J et al (2017) Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood 129:1658\u20131668","journal-title":"Blood"},{"key":"6560_CR15","first-page":"287","volume":"62","author":"Z Adam","year":"2016","unstructured":"Adam Z, Szturz P, Krej\u010d\u00ed M et al (2016) [Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature]. Vnitr Lek 62:287\u2013298","journal-title":"Vnitr Lek"},{"key":"6560_CR16","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00277-018-3347-0","volume":"97","author":"Y Dong","year":"2018","unstructured":"Dong Y, Zhang L, Nong L et al (2018) Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. Ann Hematol 97:1641\u20131647","journal-title":"Ann Hematol"},{"key":"6560_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-024-01588-9","volume":"17","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yin X, Ding S et al (2024) Continuous therapy in HHV-8 negative multicentric Castleman disease and prolonged progression-free survival. J Hematol Oncol 17:60","journal-title":"J Hematol Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06560-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06560-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06560-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:15:10Z","timestamp":1767485710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06560-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":17,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6560"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06560-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed according to the principles of the declarations of the Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}